Abnova Business Summary

Abnova Corporation (4133.TW) is the world’s largest monoclonal antibody manufacturer, utilizing a proprietary high-throughput "Genomic-to-Antibody" pipeline to generate revenue through the sale of research-grade reagents, diagnostic kits, and specialized contract research services (CRO). The company’s business model is anchored by a massive catalog of over 100,000 antibodies and proteins, supplemented by a clinical diagnostics division focusing on liquid biopsy and circulating tumor cell (CTC) isolation technologies. Recently, Abnova has expanded into high-growth segments including mRNA production services (RNAutomation) and nanoCAR-T cell therapy tools, diversifying its income streams beyond traditional proteomic reagents. In the global market, Abnova competes with major life science entities such as Thermo Fisher Scientific, Abcam (a Danaher subsidiary), Bio-Techne, and GenScript Biotech. It maintains a competitive edge as a primary manufacturer with integrated automation, positioning itself as a high-volume, cost-efficient upstream supplier for pharmaceutical and academic research. The company was founded by Dr. Wilbur Huang, who serves as Chairman and provides the core strategic vision for the firm’s industrial-scale biotechnology approach. Dr. Huang, an MD from Northwestern University, leveraged his medical and entrepreneurial background to pioneer the company’s automated production systems. Day-to-day operations are led by President and General Manager Jih Pei Ju, who brings extensive technical expertise from her tenure in the company’s Bio-Reagent Division and a Master’s degree from National Taiwan University. The leadership team is supported by a board featuring significant institutional backing from Taiwanese investment firms, including Kun-Mu Investment and Bo-Hong Investment. This executive structure has successfully transitioned Abnova from a pure reagent supplier to a clinical-stage diagnostic and therapeutic partner, solidifying its position as a cornerstone of Taiwan’s biotechnology sector on the TWSE.